ノースカロライナにおける脳腫瘍の臨床試験
ノースカロライナ内の拠点で、脳腫瘍に関する20件の研究が参加者を募集しています。
ノースカロライナ内の都市
公式研究テキスト（英語）
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Duke University School of Medicine, Durham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT05786924A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Local Institution - 0100, Durham
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07492680A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- Wake Forest University at Clemmons, Clemmons
- Southeastern Medical Oncology Center-Clinton, Clinton
- Southeastern Medical Oncology Center-Goldsboro, Goldsboro
- 他4件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/15更新 · NCT04511013A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Duke Cancer Institute, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06253871Targeted Pediatric High-Grade Glioma Therapy
- Duke University Health System, Durham
被験者募集中観察研究
12 Months – 39 Years · 全性別 · 2026/09/08更新 · NCT05839379A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
- Duke University, Durham
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/08更新 · NCT07428616Study of Olutasidenib and Temozolomide in HGG
- Duke University Health System, Durham
被験者募集中第2相
12歳〜39歳 · 全性別 · 2026/09/01更新 · NCT06161974ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
- Duke University Medical Center, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/24更新 · NCT05609994Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
- Atrium Health Wake Forest Baptist, Winston-Salem
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/08/19更新 · NCT05317858MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets
- University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill
被験者募集中観察研究
18歳以上 · 全性別 · 2026/08/14更新 · NCT04073966B6 Administration for Levetiracetam-Associated Neurobehavioral Changes and Epilepsy
- Duke University Medical Center, Durham
被験者募集中
18歳以上 · 全性別 · 2026/07/29更新 · NCT07271966Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
- Vidant Heath - ECU Medical Center, Greenville
- Atlantic Brain & Spine, Wilmington
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/22更新 · NCT04427384Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/17更新 · NCT05692635REMASTer: REcurrent Brain Metastases After SRS Trial
- Wake Forest Baptist Medical Center, Winston-Salem
被験者募集中
18歳以上 · 全性別 · 2026/06/18更新 · NCT05124912Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- Cone Health Cancer Center, Greensboro
- Wake Forest University Health Sciences, Winston-Salem
被験者募集中第3相
18歳以上 · 全性別 · 2026/06/09更新 · NCT03550391Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Duke University Health System, Durham
被験者募集中第2相
12 Months – 39 Years · 全性別 · 2026/05/29更新 · NCT05843253Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
- Lineberger Comprehensive Cancer Center, Chapel Hill
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/22更新 · NCT05366179Key Longitudinal Associations With Risk and Glioblastoma Outcomes
- Duke University, Durham
被験者募集中観察研究
18歳以上 · 全性別 · 2026/01/20更新 · NCT06625684Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors
- Duke Cancer Center, Durham
被験者募集中観察研究
18歳以上 · 全性別 · 2025/11/19更新 · NCT05480644APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- University of North Carolina, Chapel Hill
被験者募集中第2相
18歳以上 · 全性別 · 2025/06/27更新 · NCT03175224ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。